A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Open to people ages 12 years and up

• Signed Informed Consent Form
• For adolescent patients: Informed Consent Form for study participation signed by the parents or a legal guardian, and patient assent obtained, as per local requirements
• Ability to comply with the study protocol procedures
• Confirmed diagnosis of gMG (anti-AChR, anti-MuSK or anti-LRP4 present at screening)
• A total MG-ADL score of ≥ 5 points at screening with more than 50% of this score attributed to non-ocular items
• MGFA severity Class II-IV
• Ongoing gMG treatment at a stable dose
• For female patients of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab.

• History of thymectomy within 12 months prior to screening
• Ocular MG (MGFA Class I) and myasthenic crisis (MGFA Class V) within the last 3 months prior to screening
• Known disease other than gMG that would interfere with the course and conduct of the study
• Positive screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV)
• Evidence of latent or active tuberculosis (excluding patients receiving chemoprophylaxis for latent tuberculosis infection)
• Receipt of live or live attenuated vaccine within 6 weeks prior to baseline
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the last dose